Arrowhead Pharmaceuticals - ARWR Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $53.45
Forecasted Upside: 123.47%
Number of Analysts: 12
Breakdown:
0 Sell Ratings
4 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$23.92 As of 04/22/2024 01:00 AM ET

▲ +1.59 (7.12%)

1 month | 3 months | 12 months

Get New Arrowhead Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ARWR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARWR

^$53.45

▲ +123.47% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $53.45, with a high forecast of $90.00 and a low forecast of $34.00. The average price target represents a 123.47% upside from the last price of $23.92.

Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Arrowhead Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/30/2022

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/28/2023

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/28/2023

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/27/2023

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/25/2023

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/23/2024

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/23/2024

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/22/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/8/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$90.00	Low
2/7/2024	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$34.00 ➝ $36.00	Low
2/7/2024	Citigroup	Boost Target	Neutral ➝ Neutral	$33.00 ➝ $34.00	Low
2/7/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$50.00	Low
1/16/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$50.00	Low
1/2/2024	Bank of America	Boost Target	Buy ➝ Buy	$29.00 ➝ $37.00	Low
12/4/2023	Bank of America	Initiated Coverage	Buy	$29.00	Low
11/30/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$50.00	Low
11/30/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $37.00	Low
9/19/2023	Citigroup	Initiated Coverage	Neutral	$33.00	Low
8/9/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$90.00	Low
8/8/2023	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$60.00	Low
8/8/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$60.00	Low
8/8/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$79.00 ➝ $47.00	Low
7/21/2023	TD Cowen	Initiated Coverage	Outperform		Low
7/20/2023	B. Riley	Reiterated Rating	Buy ➝ Buy	$55.00	Low
6/30/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$90.00	Low
6/2/2023	Piper Sandler	Boost Target		$52.00 ➝ $59.00	Low
5/12/2023	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
5/12/2023	SVB Securities	Downgrade	Outperform ➝ Market Perform	$40.00	Low
5/3/2023	500.com	Reiterated Rating	Reiterates		Low
4/26/2023	Sumitomo Mitsui Financial Group	Initiated Coverage	Outperform	$80.00	Low
4/12/2023	SVB Leerink	Upgrade	Market Perform ➝ Outperform		Low
4/12/2023	SVB Securities	Upgrade	Market Perform ➝ Outperform	$21.00 ➝ $35.00	Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Market Perform	$27.00	Low
2/10/2023	HC Wainwright	Reiterated Rating	Buy	$90.00	Low
2/10/2023	Chardan Capital	Reiterated Rating	Buy	$60.00	Low
2/8/2023	B. Riley	Lower Target	Buy	$59.00 ➝ $55.00	Low
2/7/2023	Royal Bank of Canada	Lower Target	Outperform	$83.00 ➝ $77.00	Low
2/7/2023	Piper Sandler	Lower Target	Overweight	$55.00 ➝ $52.00	Low
2/7/2023	Robert W. Baird	Lower Target	Outperform	$60.00 ➝ $58.00	Low
1/10/2023	Chardan Capital	Lower Target		$82.00 ➝ $60.00	Low
1/9/2023	Piper Sandler	Lower Target		$64.00 ➝ $55.00	Low
12/6/2022	HC Wainwright	Lower Target	Buy	$110.00 ➝ $90.00	Low
11/30/2022	The Goldman Sachs Group	Reiterated Rating	Buy	$65.00 ➝ $66.00	Low
11/30/2022	B. Riley	Lower Target	Buy	$65.00 ➝ $59.00	Low
11/29/2022	Jefferies Financial Group	Lower Target	Buy	$92.00 ➝ $75.00	Low
11/29/2022	Morgan Stanley	Lower Target	Equal Weight	$41.00 ➝ $37.00	Low
11/29/2022	SVB Leerink	Lower Target	Market Perform	$33.00 ➝ $31.00	Low
11/10/2022	SVB Leerink	Boost Target	Market Perform	$32.00 ➝ $33.00	Low
11/9/2022	Piper Sandler	Lower Target	Overweight	$72.00 ➝ $64.00	Low
9/9/2022	Morgan Stanley	Initiated Coverage	Equal Weight	$41.00	Low
8/8/2022	The Goldman Sachs Group	Boost Target	Buy	$58.00 ➝ $65.00	Low
8/5/2022	Chardan Capital	Boost Target		$80.00 ➝ $82.00	Low
7/14/2022	HC Wainwright	Reiterated Rating	Buy	$110.00	Low
6/3/2022	HC Wainwright	Boost Target	Buy	$100.00 ➝ $110.00	High
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$90.00 ➝ $66.00	High
5/11/2022	Piper Sandler	Lower Target		$89.00 ➝ $72.00	High
5/11/2022	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$71.00 ➝ $60.00	High
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/23/2022	HC Wainwright	Reiterated Rating	Buy	$100.00	High
2/8/2022	HC Wainwright	Reiterated Rating	Buy	$100.00	Low
2/3/2022	SVB Leerink	Lower Target	Market Perform	$46.00 ➝ $36.00	Low
1/28/2022	SVB Leerink	Boost Target	Market Perform	$45.00 ➝ $46.00	High
1/19/2022	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy		High
11/23/2021	SVB Leerink	Boost Target	Market Perform	$44.00 ➝ $45.00	Low
8/10/2021	HC Wainwright	Boost Target	Buy	$95.00 ➝ $100.00	Medium
8/6/2021	Chardan Capital	Lower Target	Buy	$97.00 ➝ $94.00	High
7/2/2021	HC Wainwright	Reiterated Rating	Buy	$95.00	N/A
7/2/2021	Piper Sandler	Lower Target	Overweight	$109.00 ➝ $89.00	High
6/27/2021	SVB Leerink	Reiterated Rating	Hold		High
6/21/2021	Piper Sandler	Boost Target	Overweight ➝ Overweight	$99.00 ➝ $109.00	Low
2/8/2021	Citigroup	Boost Target		$90.00 ➝ $110.00	Medium
2/8/2021	B. Riley	Boost Target	Buy	$98.00 ➝ $106.00	High
2/5/2021	Piper Sandler	Boost Target	Overweight	$90.00 ➝ $99.00	High
2/5/2021	Chardan Capital	Boost Target	Buy	$81.00 ➝ $97.00	High
2/5/2021	HC Wainwright	Boost Target	Buy	$90.00 ➝ $95.00	High
12/21/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$75.00	High
12/15/2020	UBS Group	Initiated Coverage	Buy	$95.00	Low
11/24/2020	Royal Bank of Canada	Boost Target	Positive ➝ Outperform	$62.00 ➝ $80.00	High
11/24/2020	Cantor Fitzgerald	Boost Target	Overweight	$58.00 ➝ $80.00	High
11/24/2020	SVB Leerink	Lower Target	Market Perform	$35.00 ➝ $34.00	High
11/19/2020	Smith Barney Citigroup	Initiated Coverage	Buy	$90.00	Low
11/17/2020	B. Riley	Boost Target	Buy ➝ Positive	$68.00 ➝ $98.00	Low
11/16/2020	Robert W. Baird	Boost Target	Outperform	$70.00 ➝ $75.00	Low
10/12/2020	B. Riley	Boost Target		$57.00 ➝ $68.00	Low
10/12/2020	HC Wainwright	Reiterated Rating	Buy		Low
10/8/2020	Piper Sandler	Boost Target		$80.00 ➝ $90.00	High
9/17/2020	SVB Leerink	Boost Target	Market Perform	$29.00 ➝ $31.00	Low
8/24/2020	HC Wainwright	Reiterated Rating	Buy		Low
7/29/2020	Chardan Capital	Reiterated Rating	Buy	$81.00	High
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$62.00	High
5/10/2020	B. Riley	Reiterated Rating	Buy	$57.00	High
5/8/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00 ➝ $58.00	High
5/8/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$58.00	High
4/15/2020	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$55.00 ➝ $60.00	High
3/31/2020	B. Riley	Reiterated Rating	Buy	$57.00	High
3/24/2020	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$29.00	Medium
3/17/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$45.00	Medium
3/13/2020	B. Riley	Lower Target	Buy	$83.00 ➝ $57.00	High
2/7/2020	Jefferies Financial Group	Boost Target		$77.00 ➝ $80.00	Medium
2/6/2020	B. Riley	Reiterated Rating	Buy	$83.00	High
2/6/2020	Cantor Fitzgerald	Boost Target	Neutral	$50.00 ➝ $55.00	High
1/24/2020	B. Riley	Reiterated Rating	Buy	$83.00	Low
1/21/2020	SVB Leerink	Initiated Coverage	Underperform	$32.00	High
12/12/2019	Oppenheimer	Initiated Coverage	Hold		Medium
12/9/2019	Piper Sandler Companies	Boost Target	Overweight	$72.00 ➝ $80.00	Medium
11/29/2019	Chardan Capital	Reiterated Rating	Buy	$45.00 ➝ $81.00	Medium
11/27/2019	B. Riley	Reiterated Rating	Buy	$59.00 ➝ $83.00	High
11/26/2019	S&P Equity Research	Reiterated Rating	Buy		Medium
11/26/2019	Piper Sandler Companies	Reiterated Rating	Overweight	$54.00 ➝ $72.00	High
11/25/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$39.00 ➝ $70.00	High
11/19/2019	Cantor Fitzgerald	Reiterated Rating	Neutral	$24.00 ➝ $50.00	Medium
11/13/2019	B. Riley	Boost Target	Buy	$46.00 ➝ $59.00	Low
10/24/2019	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$39.00	High
10/22/2019	Chardan Capital	Boost Target	Buy	$32.00 ➝ $45.00	High
10/21/2019	B. Riley	Set Target	Buy	$46.00	High
10/20/2019	Piper Sandler Companies	Boost Target	Overweight	$50.00 ➝ $54.00	Low
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Neutral		Low
10/2/2019	Robert W. Baird	Initiated Coverage	Outperform	$39.00	Medium
9/16/2019	Piper Sandler Companies	Reiterated Rating	Overweight	$50.00	Medium
8/19/2019	B. Riley	Boost Target	Buy	$32.00 ➝ $46.00	High
8/6/2019	Piper Sandler Companies	Boost Target	Overweight	$33.00 ➝ $50.00	Low
6/27/2019	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$24.00	High
5/28/2019	B. Riley	Boost Target	Buy	$26.00 ➝ $32.00	Low
5/13/2019	B. Riley	Boost Target	Buy	$19.00 ➝ $26.00	High

(Data available from 4/23/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

9 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/25/2023

2 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/25/2023

0 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/24/2023

7 very positive mentions
11 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/24/2023

10 very positive mentions
13 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/23/2024

12 very positive mentions
16 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

2/22/2024

21 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/23/2024

9 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/22/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $23.92

$22.24

$24.30

50 Day Range

MA: $28.53

$22.33

$36.08

52 Week Range

Now: $23.92

$20.67

$42.48

Volume

1,080,383 shs

Average Volume

1,481,111 shs

Market Capitalization

$2.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?: The following equities research analysts have issued research reports on Arrowhead Pharmaceuticals in the last twelve months: 500.com Limited, B. Riley, Bank of America Co., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., HC Wainwright, Morgan Stanley, Piper Sandler, Royal Bank of Canada, StockNews.com, Sumitomo Mitsui Financial Group, Inc., SVB Leerink LLC, SVB Securities, and TD Cowen.
View the latest analyst ratings for ARWR.
What is the current price target for Arrowhead Pharmaceuticals?: 11 Wall Street analysts have set twelve-month price targets for Arrowhead Pharmaceuticals in the last year. Their average twelve-month price target is $53.45, suggesting a possible upside of 123.5%. HC Wainwright has the highest price target set, predicting ARWR will reach $90.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $34.00 for Arrowhead Pharmaceuticals in the next year.
View the latest price targets for ARWR.
What is the current consensus analyst rating for Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals currently has 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARWR.
What other companies compete with Arrowhead Pharmaceuticals?: Other companies that are similar to Arrowhead Pharmaceuticals include HUTCHMED, ACADIA Pharmaceuticals, IDEAYA Biosciences, MoonLake Immunotherapeutics and Amicus Therapeutics. Learn More about companies similar to Arrowhead Pharmaceuticals.
How do I contact Arrowhead Pharmaceuticals' investor relations team?: Arrowhead Pharmaceuticals' physical mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company's listed phone number is (626) 304-3400 and its investor relations email address is [email protected]. The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com. Learn More about contacing Arrowhead Pharmaceuticals investor relations.

Arrowhead Pharmaceuticals - ARWR Stock Price Target and Predictions

Analyst Price Target for ARWR

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.87 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

What is the current price target for Arrowhead Pharmaceuticals?

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

What other companies compete with Arrowhead Pharmaceuticals?

How do I contact Arrowhead Pharmaceuticals' investor relations team?